Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 2305.06076

The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design

Samantha E. Clark·Ruth Etzioni·Jerry Radich·Zachary Marcum·Anirban Basu
View original source ↗Read source document ↗Export metadata ↓

Abstract

Objective To assess the price elasticity of branded imatinib in chronic myeloid leukemia (CML) patients on Medicare Part D to determine if high out-of-pocket payments (OOP) are driving the substantial levels of non-adherence observed in this population. Data sources and study setting We use data from the TriNetX Diamond Network (TDN) United States database for the period from first availability in 2011 through the end of patent exclusivity following the introduction of generic imatinib in early 2016. Study design We implement a fuzzy regression discontinuity design to separately estimate the effect of Medicare Part D enrollment at age 65 on adherence and OOP in newly-diagnosed CML patients initiating branded imatinib. The corresponding price elasticity of demand (PED) is estimated and results are assessed across a variety of specifications and robustness checks. Data collection/extraction methods Data from eligible patients following the application of inclusion and exclusion criteria were analyzed. Principal findings Our analysis suggests that there is a significant increase in initial OOP of $232 (95% Confidence interval (CI): $102 to $362) for individuals that enrolled in Part D due to expanded eligibility at age 65. The relatively smaller and non-significant decrease in adherence of only 6 percentage points (95% CI: -0.21 to 0.08) led to a PED of -0.02 (95% CI: -0.056, 0.015). Conclusion This study provides evidence regarding the financial impact of coinsurance-based benefit designs on Medicare-age patients with CML initiating branded imatinib. Results indicate that factors besides high OOP are driving the substantial non-adherence observed in this population and add to the growing literature on PED for specialty drugs.

Explore related subjects

econ.EMstat.AP

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Samantha E. Clark, Ruth Etzioni, Jerry Radich, Zachary Marcum, Anirban Basu. 2023-05-10. The price elasticity of Gleevec in patients with Chronic Myeloid Leukemia enrolled in Medicare Part D: Evidence from a regression discontinuity design. https://arxiv.org/abs/2305.06076

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Poverty Targeting with Imperfect Information

How should antipoverty programs allocate transfers when household income is known only through noisy predictions? I formulate this as a statistical decision problem in which a policymaker chooses nonnegative transfers within a fixed budget to minimize squared deviations of post-transfer income from the poverty line. I show that the standard plug-in rule, which treats predictions as exact, is inadmissible. I then develop a nonparametric empirical Bayes allocation rule that replaces the estimated gaps with posterior mean poverty gaps. Its Bayes regret is bounded by the mean squared difference between its posterior mean gaps and the oracle's, so the budget and nonnegativity constraints do not slow its convergence to the oracle. The approach extends, with weaker guarantees, to a planner who cares only about how far households remain below the poverty line after transfers and to programs that pay a fixed set of benefit amounts. In simulations using household surveys from nine African countries, the allocations under the empirical Bayes rule reach about 1.8 times as many poor people as those under plug-in OLS with the same budget and achieve the same average poverty gap reduction with 6.7% less spending.

econ.EM↗
arXiv2026

Estimating Treatment Effects in Panel Data Without Parallel Trends

This paper proposes a novel approach for estimating treatment effects in panel data settings, addressing key limitations of the standard difference-in-differences (DID) approach. The standard approach relies on the parallel trends assumption, implicitly requiring that unobservable factors correlated with treatment assignment be unidimensional, time-invariant, and affect untreated potential outcomes in an additively separable manner. This paper introduces a more flexible framework that allows for multidimensional unobservables and non-additive separability, and provides sufficient conditions for identifying the average treatment effect on the treated. An empirical application to job displacement reveals substantially smaller long-run earnings losses compared to the standard DID approach, demonstrating the framework's ability to account for unobserved heterogeneity that manifests as differential outcome trajectories between treated and control groups.

econ.EM↗
arXiv2026

Single-Network Finite-Sample Inference in Strategic Network Formation Models

We develop a finite-sample valid inference procedure for strategic network formation models with endogenous network statistics, using only a single observed network. We impose no restrictions on network density, equilibrium selection, or the dependence structure induced by strategic interaction. Using a "bounding-by-c" technique, we obtain realization-wise sandwich inequalities whose middle term depends only on exogenous covariates and i.i.d. pairwise shocks. These inequalities deliver pathwise identifying restrictions and simulable finite-sample critical values in both parametric and semiparametric settings. Our proposed procedure is also computationally tractable: it does not involve solving, simulating, or enumerating equilibrium (sub)networks, and easily scales to networks with 10000 agents in simulations. In two empirical applications, we find statistical evidence for positive link interdependence at the 95% confidence level.

econ.EM↗